Foamix Extends Collaboration with Galderma

Published November 4th, 2009 - 10:43 GMT

 Foamix Ltd, a global leader in the development of dermatological foam
medications today announced that the company has extended its agreement with  Galderma to develop an innovative medicated foam for an additional
dermatological indication. This new treatment contains a novel drug for the
therapy of certain skin diseases.

 

    Under this agreement, Foamix will develop the foam formulation
of the product and Galderma will subsequently conduct all other activities
(clinical, non-clinical, etc). Foamix will receive staged payments on
successful completion of the technical milestones of the project.
Foamix Extends Collaboration with Galderma

REHOVOT, Israel, November 3/PRNewswire/ --     Foamix Ltd, a global leader in the
development of dermatological foam
medications today announced that the company has extended its agreement with
Galderma to develop an innovative medicated foam for an additional
dermatological indication. This new treatment contains a novel drug for the
therapy of certain skin diseases.

 

    Under this agreement, Foamix will develop the foam formulation
of the product and Galderma will subsequently conduct all other activities
(clinical, non-clinical, etc). Foamix will receive staged payments on
successful completion of the technical milestones of the project.


© 2000 - 2019 Al Bawaba (www.albawaba.com)

You may also like